This article is for informational purposes only. Cannabis can interact with many medications. Always consult your healthcare provider before combining cannabinoid products with any medication.
By Kratom CBD Direct Safety Desk | Last verified: July 2026
Overview: Why CYP450 Inhibition Matters
Cannabidiol (CBD) is metabolized and also inhibits a family of liver enzymes called cytochrome P450 (CYP450). These enzymes are responsible for breaking down an estimated 60% of all medications humans take. When CBD slows their function, drug levels in your bloodstream can rise unexpectedly—sometimes to therapeutic failure or toxic levels.
This is not a minor interaction. The FDA issued a public health advisory in 2020 highlighting CBD's potential to alter medication metabolism. Yet many CBD users are unaware of this risk, and many CBD product labels carry no interaction warnings.
What this means: You may feel fine while CBD is silently raising your blood levels of a heart medication, blood thinner, or psychiatric drug. Interactions can develop slowly and manifest as:
- Unexpected side effects or toxicity from a medication you've been taking safely for years
- Loss of medication effectiveness (less common but possible)
- Increased bleeding risk (with anticoagulants)
- Dangerously high drug levels requiring dose adjustment
Mechanism of Risk: How CYP450 Inhibition Works
Your liver contains multiple cytochrome P450 enzymes. Each specializes in metabolizing different drugs. The main players in CBD interactions are:
- CYP3A4: Metabolizes ~50% of all drugs (statins, immunosuppressants, protease inhibitors, some cancer drugs).
- CYP2C9: Processes warfarin, NSAIDs, and some diabetes medications.
- CYP2C19: Breaks down SSRIs, certain antifungals, and proton pump inhibitors.
- CYP2D6: Metabolizes antidepressants, antipsychotics, and some pain medications.
When you consume CBD, it competes for these enzymes and can inhibit their function—especially at higher doses (>200 mg/day). This is called the “grapefruit effect” because grapefruit similarly inhibits CYP3A4 and causes well-documented drug interactions.
The dose matters: Low-dose CBD (10–50 mg/day) may pose minimal risk for most people. Higher doses (200+ mg/day) significantly increase inhibition and interaction risk. Individual variation in enzyme expression also plays a role—some people metabolize CBD faster or slower than others.
Specific Drug Interactions: Drug Classes and Examples
Below are the medication classes and specific drugs that carry documented or suspected CBD interaction risk:
Anticoagulants (Blood Thinners)
Mechanism: CBD inhibits CYP2C9, which metabolizes warfarin. Elevated warfarin levels increase bleeding risk.
Drugs: Warfarin (Coumadin), dabigatran (Pradaxa)
Risk: HIGH. Increased international normalized ratio (INR) and bleeding complications have been reported.
Statins (Cholesterol Medications)
Mechanism: Many statins (atorvastatin, simvastatin) are CYP3A4 substrates. CBD inhibition can elevate statin levels and myopathy risk.
Drugs: Atorvastatin (Lipitor), simvastatin (Zocor), lovastatin
Risk: MODERATE to HIGH. Muscle pain and liver enzyme elevation possible.
Antidepressants & Anxiolytics (SSRIs, SNRIs)
Mechanism: SSRIs like sertraline and paroxetine are CYP2D6 and CYP2C19 substrates. CBD inhibition may raise levels.
Drugs: Sertraline (Zoloft), paroxetine (Paxil), fluoxetine (Prozac), venlafaxine (Effexor)
Risk: MODERATE. Serotonin syndrome (rare but serious) or increased side effects possible at higher CBD doses.
Antiarrhythmic Drugs
Mechanism: Flecainide, propafenone, and amiodarone are CYP2D6 or CYP3A4 substrates.
Drugs: Flecainide (Tambocor), propafenone (Rythmol), amiodarone (Cordarone)
Risk: HIGH. Narrow therapeutic window; elevated levels can cause dangerous arrhythmias.
Immunosuppressants (Organ Transplant, Autoimmune)
Mechanism: Tacrolimus, cyclosporine, and everolimus are CYP3A4 substrates.
Drugs: Tacrolimus (Prograf), cyclosporine (Neoral), everolimus (Afinitor)
Risk: HIGH. Loss of transplant protection or autoimmune flare possible if levels drop; toxicity if they rise.
Seizure Medications
Mechanism: Phenytoin and clobazam are CYP2C9 and CYP3A4 substrates; CBD may elevate levels.
Drugs: Phenytoin (Dilantin), clobazam (Onfi), topiramate (Topamax)
Risk: MODERATE to HIGH. Seizure breakthrough or toxicity possible.
Opioids (Pain Medications)
Mechanism: Codeine and some methadone metabolism involves CYP2D6.
Drugs: Codeine, methadone
Risk: MODERATE. Elevated opioid levels increase CNS depression, overdose, and respiratory depression risk.
Benzodiazepines (Sedatives)
Mechanism: Alprazolam, midazolam are CYP3A4 substrates; CBD adds CNS depression risk.
Drugs: Alprazolam (Xanax), midazolam (Versed), diazepam (Valium)
Risk: MODERATE to HIGH. Excessive sedation, respiratory depression, overdose risk.
Proton Pump Inhibitors (Acid Reflux)
Mechanism: Omeprazole and lansoprazole are CYP2C19 and CYP3A4 substrates.
Drugs: Omeprazole (Prilosec), lansoprazole (Prevacid)
Risk: LOW to MODERATE. Elevated levels unlikely to cause harm, but possible.
Antihistamines & Decongestants
Mechanism: Some antihistamines (terfenadine, astemizole—now withdrawn) and pseudoephedrine are CYP3A4 substrates.
Drugs: Cetirizine (Zyrtec), loratadine (Claritin)
Risk: LOW. Modern antihistamines have large margins of safety; risk is minimal.
Interaction Severity Table
| Drug / Class | Enzyme Pathway | Interaction Type | Severity | Recommended Action |
|---|---|---|---|---|
| Warfarin (Coumadin) | CYP2C9 | Elevated drug level → bleeding risk | HIGH | Avoid or require INR monitoring; consult MD |
| Atorvastatin (Lipitor) | CYP3A4 | Elevated drug level → myopathy | MODERATE–HIGH | Medical supervision; monitor muscle symptoms |
| Sertraline (Zoloft) | CYP2C19, CYP2D6 | Elevated drug level; serotonin syndrome risk | MODERATE | Start low CBD dose; monitor mood/side effects |
| Tacrolimus (Prograf) | CYP3A4 | Elevated drug level → organ rejection risk | HIGH | Avoid; consult transplant team before use |
| Phenytoin (Dilantin) | CYP2C9, CYP3A4 | Elevated drug level → ataxia, toxicity | MODERATE–HIGH | Avoid; seizure control may be affected |
| Alprazolam (Xanax) | CYP3A4 + CNS depression | Elevated drug level + additive CNS depression | MODERATE–HIGH | Avoid combination; respiratory depression risk |
| Methadone | CYP2D6 + CNS depression | Elevated drug level + additive CNS depression | HIGH | Avoid; overdose and respiratory depression risk |
Leave a Reply